


CM1406 *EpiChemBio* Joint group meeting: Epigenetic reprogramming and epigenetic technologies



SPEAKERS

Corentin Bon (Institute Pasteur, Paris, France)

Vânia Camilo (Portuguese Oncology University of Porto, Porto, Portugal)

Pierre-Antoine Defossez (Epigenetics & Cell Fate Centre, Paris, France) a Keynote speaker

Ivan Devesa (University of Cordoba, Cordoba, Spain)

Claire Francastel (Paris Diderot University, Sorbonne Paris Cité, France) a Keynote speaker

Sheraz Gul (European Screening Port, Germany)

Daniel CB Jeffery (Institut Curie, Paris, France) a Keynote speaker

Carmen Jeronimo (Portuguese Oncology University of Porto, Porto, Portugal)

Bozena Kaminska (Nencki Institute, Warsaw, Poland)

Jakub Mieczkowski (Nencki Institute, Warsaw, Poland)

Marianne Rots (University Medical Center Groningen, Groningen, Netherlands)

Wim Vanden Berghe (University of Antwerp, Belgium)

Melita Vidakovic (University of Belgrade, Serbia)

Pissarro Boulevard Montmartre La Nuit



CM1406: Epigenetic Chemical Biology



Venue:
Le Centre Scientifique de
l'Académie Polonaise des
Sciences, 74, rue
Lauriston, Paris, France

PROGRAMME

DAY 1, January 21st 2019

9:30	Coffee and registration
10:00-10:30	Welcome and update by WG Leaders

Session I

10:30- 11:30	Invited lecture 1- Pierre-Antoine Defossez (Epigenetics & Cell Fate Centre, Paris) <i>A histone mimic couples DNA methylation to DNA replication</i>
11:30	ESR 1 - Jakub Mieczkowski (Nencki Institute, Warsaw, Poland) <i>Reprogramming epigenetic landscape of glioma stem cells</i>
11:45	ESR 2 - Vânia Camilo (Portuguese Oncology University of Porto, Porto, Portugal) <i>Hydralazine a new hope for castration resistant prostate cancer patients?</i>

12:00- 13:00	Lunch break (on site)
--------------	-----------------------

Session II

13:00 -14:00	Invited lecture 2- Claire Francastel (Epigenetics & Cell Fate Centre, UMR7216 CNRS, Paris Diderot University, Sorbonne Paris Cité) <i>DNA methylation alterations in rare diseases</i>
14:00-14:20	Marianne Rots (University Medical Center Groningen, Groningen, Netherlands) <i>The Hypes and Hopes of Epigenetic Editing</i>
14:20-14:40	Wim Vanden Berghe (University of Antwerp, Belgium) <i>Epigenomic crosstalk microbiome-host in health/disease</i>
14:40-14:55	Ivan Devesa (PhD student @ Roldán-Arjona's Lab, Cordoba, Spain) <i>Reprogramming the methylome of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase</i>

14:55-15:30	Coffee break
-------------	--------------

Session III

15:30-15:50	Bozena Kaminska (Nencki Institute, Warsaw, Poland) <i>Inhibition of histone methyltransferase G9a sensitizes glioma cells to chemotherapeutics</i>
15:50-16:10	Carmen Jeronimo (Portuguese Oncology University of Porto, Porto, Portugal) <i>Anti-Neoplastic Activity of Newly Synthesized DNMTi in Renal Tumors</i>
16:10-16:25	Corentin Bon (PhD student @ Arimondo's Lab, Institute Pasteur, Paris, France) <i>Targeting DOT1L in MLL rearranged leukaemia cells</i>
16:25-17:30	Short Pitches

17:30	Closing words
-------	---------------



DAY 2, January 22nd 2019**Session I**

9:00-10:00	Invited lecture 3 - Daniel CB Jeffery (Institut Curie, Chromatin Dynamics team: G. Almouzni, Paris, France) <i>CENP-A, the centromeric histone variant, and cancer: radio sensitivity and resistance when epigenetic marks go awry</i>
10:00-10:30	Melita Vidakovic (University of Belgrade, Serbia) <i>Epigenetic regulation of epithelial-mesenchymal transition: potential application in fibroproliferative diseases</i>
10:30-11:00	Sheraz Gul (European Screening Port, Germany) <i>A collaborative COST Action ADME - Tox assay panel to progress compounds in the drug discovery value chain</i>

11:00-11:30

Coffee break**Session II**

11:30-13:00	Discussion on future EU applications
13:00-14:00	Round table discussions on: a) Epigenetic Technology: New generation techniques and Bioinformatics b) Epigenetic Reprogramming: new experimental models
14:00-15:00	Lunch break

15:00-16:30

Presentations of outcome round table discussions (4 Groups)

16:30

Closing words